XtalPi will receive ~$250M up front and milestones. The collaboration focuses on using AI and robotics in drug discovery
The collaboration will use XtalPi’s integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target. XtalPi brings together AI “dry lab” algorithms and “wet lab” robotics to drive innovation
The collaboration will leverage the AI drug discovery solution to create a novel compound which will be advanced by Lilly through clinical and commercial development. XtalPi’s ID4Inno small-molecule drug discovery platform helps to create and explore a target-specific mega-chemical space as well as identify a promising lead series
Ref: PRNewswire | Image: XtalPi
Related News:- XtalPi Collaborated with CK Life Sciences to Develop AI-Empowered Tumour Vaccine Research and Development Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
